Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
Global HIV Strategic Information Working Group
For Populations At Risk For HIV
Responding to a poliovirus event and outbreak, Part 1: General (SOPs) describes the general principles and steps to facilitate timely and effective responses to poliovirus events and outbreaks, and incorporate lessons learned from recent previous outbreak response efforts. This document summarizes r...oles and responsibilities of national governments and Global Polio Eradication Initiative (GPEI) partners.
Effective 01 November 2017 until 30 April 2018
more
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 5-11 November 2017 and includes updates on measles, rubella, chikungunya, West Nile virus, Plague, monkeypox, legionnair...es's disease, influenza and Marburg virus disease.
more
Establishing trauma referral pathways to provide urgent life-saving assistance for displaced populations and civilians remaining in Ar-Raqqa.
In July 2017, a WHO team comprising an external trauma care specialist and two WHO staff members visited the governorates of Ar-Raqqa and neighbouring Al-Ha...sakeh to assess the situation
more
National Tuberculosis and Leprosy Conrol Programme
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more